FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 藥師幫股份有限公司 (於開曼群島註冊成立之有限公司) 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09885 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 20,000,000,000 | USD | | 0.0000025 USD | | 50,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 20,000,000,000 | USD | | 0.0000025 USD | | 50,000 | 本月 ...

Market Performance - Hang Seng Index fell by 403 points, or 1.6%, closing at 24,773 points[1] - Shanghai Composite Index dropped by 42 points, or 1.18%, closing at 3,573 points[2] - S&P 500 decreased by 23 points, or 0.4%, closing at 6,339 points, marking the third consecutive day of decline[2] Currency and Economic Indicators - Hong Kong Monetary Authority bought HKD 39.25 billion during New York session due to a weak HKD[1] - People's Bank of China conducted a 7-day reverse repo operation of CNY 283.2 billion at a steady rate of 1.4%[2] - July's official manufacturing PMI in China fell to 49.3, below expectations[2] Real Estate and Corporate Performance - Top 100 real estate companies in China reported total sales of CNY 2.07 trillion in the first seven months, a year-on-year decline of 13.3%[4] - Internet and related services companies in China generated revenue of CNY 961.3 billion in H1, a year-on-year growth of 3.1%[4] - Sinopec expects H1 2025 net profit to be between CNY 20.1 billion and CNY 21.6 billion, a year-on-year decline of 39.5% to 43.7%[6] Automotive Sector - XPeng Motors delivered 36,717 smart electric vehicles in July, a year-on-year increase of 229%[7] - Cumulative deliveries exceeded 800,000 units as of July, with a total of 233,906 units delivered in the first seven months, marking a 270% year-on-year growth[7]

Core Viewpoint - The company, YaoShibang (09885), has announced a positive earnings forecast, expecting a significant increase in profit for the upcoming half-year period, leading to a rise in its stock price by over 3% following the announcement [1]. Group 1: Earnings Forecast - YaoShibang anticipates that the profit attributable to shareholders for the half-year ending June 30, 2025, will be no less than RMB 70 million, which is more than three times the RMB 21.8 million profit for the half-year ending June 30, 2024 [1]. - The board attributes the expected increase in profit to the company's strong industry position and competitive advantages, which have allowed for steady revenue growth [1]. Group 2: Business Performance Drivers - The sustained high demand for the company's proprietary brand products, which have a high gross margin, is contributing to the growth of this business segment [1]. - The company has a solid technological foundation, and continuous improvements in digital capabilities are enhancing the operational efficiency of its core platform and self-operated businesses [1].

Core Viewpoint - The Hang Seng Healthcare Index (HSHCI) has shown strong performance, with significant increases in constituent stocks and the Hang Seng Healthcare ETF, driven by ongoing innovation and M&A activities in the pharmaceutical sector [3][4]. Group 1: Market Performance - As of August 1, 2025, the HSHCI rose by 1.15%, with notable gains from stocks such as Yaoshi Bang (up 4.87%) and Gushengtang (up 4.62%) [3]. - The Hang Seng Healthcare ETF (513060) increased by 1.46%, with a latest price of 0.7 yuan, and has accumulated a 4.58% rise over the past week [3]. - The ETF recorded a turnover rate of 5.66% and a trading volume of 4.53 billion yuan, with an average daily trading volume of 33.29 billion yuan over the past week, ranking first among comparable funds [3][4]. Group 2: Fund Growth and Performance - The Hang Seng Healthcare ETF saw a significant scale increase of 27.99 million yuan over the past week, placing it in the top third of comparable funds [4]. - The ETF's latest financing buy-in amount reached 288 million yuan, with a financing balance of 218 million yuan [4]. - Since its inception, the ETF has achieved a net value increase of 31.51% over the past two years, ranking 16th out of 90 QDII equity funds [4]. Group 3: Valuation and Index Composition - The HSHCI's latest price-to-earnings ratio (PE-TTM) stands at 32.12, indicating a valuation below 83.19% of the historical range over the past three years, suggesting it is at a historical low [5]. - The top ten weighted stocks in the HSHCI account for 62.14% of the index, including companies like BeiGene and WuXi Biologics [5].

董事会认为，集团上述预期利润增加主要得益于以下原因：(集团凭着稳固的行业领先地位及竞争优 势，持续保持收入的稳健增长；集团自有品牌产品的下游需求持续保持旺盛，该高毛利率的业务规模持 续增长，不断提升公司的毛利率水平；集团拥有扎实的科技底座，通过数字化能力的不断提升，带动核 心的平台和自营业务的运营效率不断提升。 药师帮(09885)盈喜后涨超3%，截至发稿，涨3.31%，报10.6港元，成交额1829.01万港元。 消息面上，7月31日，药师帮发布公告，预期截至2025年6月30日止半年度公司拥有人应占利润将不少于 人民币7000万元，为截至2024年6月30日止半年度公司拥有人应占利润人民币2180万元的3倍以上。 ...

Core Viewpoint - The company, Yaoshi Bang, has announced a significant increase in expected profits for the upcoming half-year period, projecting a profit of no less than RMB 70 million, which is more than three times the profit of RMB 21.8 million from the previous year [1] Group 1: Financial Performance - The expected profit for the half-year ending June 30, 2025, is projected to be at least RMB 70 million [1] - This represents an increase of over 3 times compared to the profit of RMB 21.8 million for the half-year ending June 30, 2024 [1] Group 2: Reasons for Profit Increase - The board attributes the increase in expected profits to the company's strong industry position and competitive advantages, which have allowed for steady revenue growth [1] - There is sustained strong demand for the company's proprietary brand products, contributing to the growth of this high-margin business and improving overall gross margin levels [1] - The company has a solid technological foundation, and continuous improvements in digital capabilities have enhanced the operational efficiency of its core platform and self-operated businesses [1]

Group 1: Artificial Intelligence Policy - The State Council of China has approved the "Artificial Intelligence+" action plan, aiming to promote large-scale commercial applications of AI across various sectors [1] - The plan emphasizes the importance of innovation-driven applications and the establishment of a supportive ecosystem for AI development, including enhanced computing power, algorithms, and data supply [1] - The government and state-owned enterprises are encouraged to lead by example and support the implementation of AI technologies [1] Group 2: Market Performance - The Hang Seng Index ADR fell by 0.36%, closing at 24,683.19 points, down 90.14 points from the Hong Kong market [2] - The U.S. stock market saw the Dow Jones drop by 0.74%, while notable Chinese concept stocks like NIO and Alibaba experienced gains [2] Group 3: Gaming Industry - The domestic gaming market in China achieved actual sales revenue of 168 billion yuan in the first half of 2025, marking a year-on-year growth of 14.08% [4] - The number of gaming users reached approximately 679 million, reflecting a growth of 0.72% year-on-year [4] Group 4: Economic Growth in Macau - Macau's GDP for the second quarter of 2025 grew by 5.1% year-on-year, driven by an increase in tourist arrivals and stable local consumption [5] - The preliminary GDP value for the second quarter was 100.38 billion patacas, recovering to 88.8% of the economic scale compared to the same period in 2019 [5] Group 5: Apple Inc. Financial Performance - Apple reported a third-quarter revenue of $94 billion, exceeding the expected $89.3 billion, with a year-on-year growth of approximately 10% [6][7] - iPhone sales contributed significantly, with a 13.5% increase in global sales, amounting to $44.6 billion [6][7] - The gross margin for the quarter was 46.5%, surpassing the anticipated 46% [7] Group 6: Corporate Actions - Deyou City plans to repurchase shares at HKD 0.62 per share, totaling approximately HKD 2.932 billion, as part of a privatization proposal [8] - China Aircraft Leasing is set to sell eight aircraft under lease agreements to enhance capital utilization, with the transaction expected to complete by the end of October 2025 [10] - Big Health International proposes to increase its registered capital to $50 million by adding 400 million shares [11] Group 7: Pharmaceutical Developments - BeiGene's BGB-16673 has received priority drug designation from the European Medicines Agency for treating Waldenström's macroglobulinemia [12] - Lee's Pharmaceutical's Socazolimab has been approved for first-line treatment of extensive-stage small cell lung cancer in mainland China [20]

Group 1 - KX-826 1.0% treatment for androgenetic alopecia has completed patient enrollment in Phase III clinical trial with a total of 666 patients [1] - The Phase III trial is designed as a seamless II/III phase study, with the II phase achieving primary endpoints with statistical significance and clinical relevance [1] - The trial is multi-center, randomized, double-blind, and placebo-controlled, assessing the efficacy and safety of KX-826 1.0% and 0.5% in Chinese adult male AGA patients [1] Group 2 - Hong Kong Telecom reported a 4% increase in total revenue to HKD 17.322 billion for the first half of the year [2] - Qingdao Bank's net profit for the first half of the year reached CNY 3.065 billion, a year-on-year increase of 16.05% [2] - Green Tea Group expects a profit of CNY 230 million to 237 million for the first half of the year, representing a year-on-year growth of 32% to 36% [2] Group 3 - Hengrui Medicine received approval for clinical trials of HRS-5041 tablets and other drugs [3] - Hengrui also received approval for clinical trials of SHR-8068 injection, Adalimumab injection, and Bevacizumab injection [3] Group 4 - Lee's Pharmaceutical's Socazolimab has been approved for first-line treatment of extensive-stage small cell lung cancer in mainland China [4] - Yihua Holdings plans to sell a property in Weihai for CNY 64.1077 million [4] - Dexin Services Group intends to acquire 100% equity of Deqing Mogan Mountain Ruijun Real Estate [4]

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company is expected to achieve a net profit attributable to shareholders of no less than RMB 70 million in the first half of 2025, which is more than three times the RMB 21.8 million net profit from the same period last year [1] - The high growth in performance is attributed to "scale effects + high gross margin business + digital empowerment" [4] - The company's self-owned brand products continue to see strong downstream demand, contributing to the growth of high-margin business and improving overall gross margin [4] - The strategic flagship product, Huoxiang Zhengqi Oral Liquid, has shown strong sales performance, with a peak daily sales exceeding RMB 5 million [4] - The company is expected to maintain high growth in the second half of 2025, driven by self-owned brands, AI, robotics, and stock buybacks [4][5] Financial Summary - The company’s total revenue is projected to be approximately RMB 20.83 billion, RMB 23.51 billion, and RMB 26.70 billion for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 16%, 13%, and 14% [6][7] - The net profit attributable to shareholders is expected to be RMB 1.49 billion, RMB 3.20 billion, and RMB 5.50 billion for the same years, with year-on-year growth rates of 395%, 116%, and 71% [6][7] - The gross margin is projected to improve from 10.89% in 2025 to 11.82% in 2027 [6] - The return on equity (ROE) is expected to increase from 6.14% in 2025 to 16.68% in 2027 [6] - The earnings per share (EPS) is projected to rise from RMB 0.22 in 2025 to RMB 0.81 in 2027 [6]

Performance Updates - 开拓药业-B (09939.HK) has completed patient enrollment for the Phase III clinical trial of KX-826 solution for androgenetic alopecia in adult males in China [2] - 李氏大药厂 (00950.HK) has received approval from the National Medical Products Administration for Socazolimab to be used in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer in mainland China [2] - 恒瑞医药 (01276.HK) has received approval for clinical trials of SHR-8068 injection, Adebali monoclonal antibody injection, and Bevacizumab injection [2] - 恒瑞医药 (01276.HK) has also received approval to conduct clinical trials for HRS-5041, intended for prostate cancer treatment [2] - 深圳高速公路股份 (00548.HK) reported toll revenue of 106 million yuan for the outer ring project in June [2] - 大成生化科技 (00809.HK) has signed an EPC contract with Northeast Electric and Liaoning Electric for boiler renovation projects, with a maximum cost of 129.1 million yuan [2] - 小黄鸭德盈 (02250.HK) has signed a contract to develop an AI marketing system to diversify revenue sources [2] Buyback and Financing Activities - 威海银行 (09677.HK) plans to issue up to approximately 758 million domestic shares and 154 million H-shares, raising nearly 3 billion yuan [2] Financial Results - 香港电讯-SS (06823.HK) reported total revenue of 17.322 billion HKD for the first half, a year-on-year increase of 4%, with a net profit of 2.07 billion HKD, also up 4% [4] - 青岛银行 (03866.HK) reported operating revenue of 7.662 billion yuan for the first half, a growth of 7.5%, and a net profit of 3.065 billion yuan, up 16.05% [4] - 中国石油化工股份 (00386.HK) expects mid-term net profit to be between 20.1 billion and 21.6 billion yuan, a year-on-year decline of 39.5%-43.7% [4] - 汽车之家-S (02518.HK) reported total revenue of 3.212 billion yuan for the first half, a decrease of 7.75%, with a net profit of 772 million yuan, down 15.99% [4] - 绿茶集团 (06831.HK) issued a profit warning, expecting mid-term net profit to be between 230 million and 237 million yuan, a year-on-year increase of approximately 32%-36% [4] - 粤海置地 (00124.HK) issued a profit warning, expecting mid-term net profit to exceed 260 million HKD, turning from loss to profit [4] - 药师帮 (09885.HK) issued a profit warning, expecting mid-term net profit to exceed 70 million yuan [4] - 中国东方教育 (00667.HK) issued a profit warning, expecting mid-term net profit to grow by 45%-50% year-on-year [4] - 中核国际 (02302.HK) issued a profit warning, expecting mid-term revenue to increase to at least 585 million HKD, with net profit of at least 9.5 million HKD [4] - 大唐环境 (01272.HK) issued a profit warning, expecting mid-term net profit to decrease to between 350 million and 400 million yuan [4] - 长江生命科技 (00775.HK) issued a profit warning, expecting mid-term net loss of approximately 150 million HKD, turning from profit to loss year-on-year [4] - 延长石油国际 (00346.HK) issued a profit warning, expecting mid-term loss of approximately 27.9 million HKD [4]